Silexion Reports $2.5 Million Third-Quarter Net Loss as SIL204 Trial Begins

Silexion Therapeutics (SLXN) reported a Q3 2026 net loss of $2.5M, or $13.70 per share, with $4.8M in cash. The company began its Phase 2/3 SIL204 trial for pancreatic cancer. R&D expenses decreased to $1.3M from $2.2M YoY, while G&A expenses rose to $1.4M. Silexion raised $6.2M through offerings and share sales, and completed a 1-for-24 reverse split.

Original reporting
Published Nov 16, 2026, 11:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Silexion Reports $2.5 Million Third-Quarter Net Loss as SIL204 Trial Begins — source image
Decision brief

The 30-second read

$SLXNBearishLow
01

Why it matters

The earnings miss and cash position create immediate downside risk, while the trial initiation may attract future funding and partnership opportunities.

02

Market read

Micro‑cap biotech investors will weigh the loss against the trial start, likely leading to short‑term price pressure.

03

What to watch

Potential for upcoming data readouts and partnership interest not reflected in the loss figures.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Silexion Therapeutics (NASDAQ: SLXN) disclosed its Q3 financials and announced the first patient dosing in its SIL204 trial for locally advanced pancreatic cancer.

Company-level read

Ticker impact

$SLXNBearishMedium confidence
Context

Silexion Therapeutics reported a Q3 net loss of $2.5M and launched the Phase 2/3 SIL204 trial for pancreatic cancer.

Expected impact

likely pressure as investors price in the loss and cash constraints

Evidence & confidence

Quarterly loss and low cash typically weigh on micro‑cap biotech stocks; however, the start of a pivotal trial may temper the decline.

Market effects

Adds to the pipeline activity narrative in the oncology biotech sector.

Limited to US biotech investors; no broader regional effect.

Minimal global impact beyond niche oncology investors.

Counterpoint

The trial start could be a catalyst for a short‑term rally if investors focus on future upside.

Key entities

  • Silexion Therapeutics

    Clinical‑stage biotech focused on oncology.

  • Tel Aviv Sourasky Medical Center

    Site of the first patient dosing for the SIL204 trial.

Related articles

$SLXNMed

Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient

$SLXNMedAI 8/10

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic

$SLXNMedAI 8/10

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics (SLXN) dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The trial combines SIL204 with standard chemotherapy. The study is being conducted at Tel Aviv Sourasky Medical Center and will expand to other sites in Israel and Germany. SIL204 is administered via a dual-route delivery strategy. The company aims to evaluate the potential of SIL204 to improve patient outcomes.

$SLXNMedAI 8/10

Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On - Silexion Therapeutics

Silexion Therapeutics (SLXN) shares surged 61% after reporting positive preclinical results for SIL204, its lead cancer therapy. The study showed dose-dependent gene silencing in KRAS-driven cancer cells. The company is advancing clinical trials. SLXN has a $1.43M market cap, down 99.27% over the past year. Shares fell 4.57% to $0.25 during regular trading.